These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. [New drugs against parasitic diseases]. Loiseau PM, Le Bras J. Rev Prat; 2007 Jan 31; 57(2):175-82. PubMed ID: 17432522 [Abstract] [Full Text] [Related]
43. 4th International Workshop in Vaccine Adjuvants and Parasitic Vaccines (adjuvant 2008). Pérez O, Harandi AM. Expert Rev Vaccines; 2008 Oct 31; 7(8):1151-3. PubMed ID: 18844589 [Abstract] [Full Text] [Related]
45. Clinical studies of experimental vaccines. Bart PA, Harari A, Pantaleo G. Curr Opin HIV AIDS; 2006 Jul 31; 1(4):286-93. PubMed ID: 19372823 [Abstract] [Full Text] [Related]
46. Antigenicity of a whole parasite vaccine as promising candidate against canine leishmaniasis. Giunchetti RC, Reis AB, da Silveira-Lemos D, Martins-Filho OA, Corrêa-Oliveira R, Bethony J, Vale AM, da Silva Quetz J, Bueno LL, França-Silva JC, Nascimento E, Mayrink W, Fujiwara RT. Res Vet Sci; 2008 Aug 31; 85(1):106-12. PubMed ID: 17950391 [Abstract] [Full Text] [Related]
47. Immunogenicity of Plasmodium yoelii merozoite surface protein 4/5 produced in transgenic plants. Wang L, Webster DE, Campbell AE, Dry IB, Wesselingh SL, Coppel RL. Int J Parasitol; 2008 Jan 31; 38(1):103-10. PubMed ID: 17681344 [Abstract] [Full Text] [Related]
51. [Development of anti-malarial vaccines and need for clinical trials in accordance with international standards in South Africa]. Doumbo OK, Djimdé AA, Théra MA. Bull Soc Pathol Exot; 2008 Jun 21; 101(3):249-53. PubMed ID: 18681219 [Abstract] [Full Text] [Related]
52. Current progress of DNA vaccine studies in humans. Lu S, Wang S, Grimes-Serrano JM. Expert Rev Vaccines; 2008 Mar 21; 7(2):175-91. PubMed ID: 18324888 [Abstract] [Full Text] [Related]
53. Evaluation of two long synthetic merozoite surface protein 2 peptides as malaria vaccine candidates. Flueck C, Frank G, Smith T, Jafarshad A, Nebie I, Sirima SB, Olugbile S, Alonso P, Tanner M, Druilhe P, Felger I, Corradin G. Vaccine; 2009 May 05; 27(20):2653-61. PubMed ID: 19428875 [Abstract] [Full Text] [Related]
54. Control of parasitic diseases in China: achievements and prospects. Mao SB. Chin Med J (Engl); 1987 Jun 05; 100(6):445-53. PubMed ID: 3115721 [No Abstract] [Full Text] [Related]
55. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response. Ramos I, Alonso A, Marcen JM, Peris A, Castillo JA, Colmenares M, Larraga V. Vaccine; 2008 Jan 17; 26(3):333-44. PubMed ID: 18093705 [Abstract] [Full Text] [Related]
56. Parasitology: the dawn of a new millennium. Hirst SI, Stapley LA. Parasitol Today; 2000 Jan 17; 16(1):1-3. PubMed ID: 10637575 [No Abstract] [Full Text] [Related]
57. [When should antiparasitic vaccines be used in medicine?]. Loutan L. Schweiz Med Wochenschr; 1996 Jul 09; 126(27-28):1202-3. PubMed ID: 8766629 [No Abstract] [Full Text] [Related]